Cancer-seeking 'smart bombs' target kidney cancer cells

June 6, 2011, Society of Nuclear Medicine

Researchers are halting kidney cancer with a novel form of radioimmunotherapy that zeroes in on antigens associated with renal cell carcinoma. Patients with progressive kidney cancer receiving up to three doses of the therapy show dramatic slowing of cancer growth and stabilization of their disease.

"This study is another step forward in developing a cancer therapy that has the potential to provide additional treatment options for patients with renal cell carcinoma," says Wim Oyen, MD, professor and chairman of the department of nuclear medicine at Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. "In many cases we were able to stop the disease from progressing and hopefully prolong patient survival without compromising their quality of life with serious adverse effects."

According to the , 50,000 Americans are diagnosed with kidney cancer each year. In adults, the most common type of kidney cancer is renal cell carcinoma.

Radioimmunotherapy is a treatment for cancer comprising medical radionuclides bound with antibodies that recognize physiological changes involved in the disease process. This specific therapy, called Lu-177-cG250, targets with the monoclonal antibody cG250, which recognizes carbonic anhydrase IX—an antigen associated with renal cell carcinoma. Once inside the body the treatment targets cancerous tissues expressing this antigen, and the radionuclide kills those cells, sparing surrounding healthy tissues.

For the purposes of this study, 20 patients with progressive, metastasized received a maximum of three doses of Lu-177-cG250 and were evaluated for toxicity and therapeutic efficacy in three-month increments. A majority of patients, 14 out of 20, were able to reach stabilization of their cancer 12 weeks after treatment. Tumor growth averages dropped from 28.5 percent increase in size before treatment to 4.1 percent during the three months after their first treatment cycle. This study shows that Lu-177-cG250 is highly effective for targeting tumor lesions and for reducing cancer proliferation in patients with progressive .

More information: Scientific Paper 359: A. Stillebroer, O. Boerman, P. Mulders, I. Desar, C. van Herpen, E. Oosterwijk, W. Oyen, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands; "Radioimmunotherapy with Lu-177 labeled anti-CAIX monoclonal antibody in advanced renal cell carcinoma," SNM's 58th Annual Meeting, June 4-8, 2011, San Antonio, TX.

Related Stories

Recommended for you

Researchers discover novel mechanism linking changes in mitochondria to cancer cell death

February 20, 2018
To stop the spread of cancer, cancer cells must die. Unfortunately, many types of cancer cells seem to use innate mechanisms that block cancer cell death, therefore allowing the cancer to metastasize. While seeking to further ...

Stem cell vaccine immunizes lab mice against multiple cancers

February 15, 2018
Stanford University researchers report that injecting mice with inactivated induced pluripotent stem cells (iPSCs) launched a strong immune response against breast, lung, and skin cancers. The vaccine also prevented relapses ...

Induced pluripotent stem cells could serve as cancer vaccine, researchers say

February 15, 2018
Induced pluripotent stem cells, or iPS cells, are a keystone of regenerative medicine. Outside the body, they can be coaxed to become many different types of cells and tissues that can help repair damage due to trauma or ...

Team paves the way to the use of immunotherapy to treat aggressive colon tumors

February 15, 2018
In a short space of time, immunotherapy against cancer cells has become a powerful approach to treat cancers such as melanoma and lung cancer. However, to date, most colon tumours appeared to be unresponsive to this kind ...

Can our genes help predict how women respond to ovarian cancer treatment?

February 15, 2018
Research has identified gene variants that play a significant role in how women with ovarian cancer process chemotherapy.

First comparison of common breast cancer tests finds varied accuracy of predictions

February 15, 2018
Commercially-available prognostic breast cancer tests show significant variation in their abilities to predict disease recurrence, according to a study led by Queen Mary University of London of nearly 800 postmenopausal women.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.